Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.

INTRODUCTION: The global threat of a chemical, biological, radiological, or nuclear (CBRN) disaster is an important priority for all government agencies involved in domestic security and public health preparedness. Radiological/nuclear (RN) attacks or accidents have become a larger focus of the United States Food and Drug administration (US FDA) over time because of their increased likeliness. Clinical signs and symptoms of a developing acute radiation syndrome (ARS) are grouped into three sub-syndromes named for the dominant organ system affected, namely the hematopoietic (H-ARS), gastrointestinal (GI-ARS), and neurovascular systems. The availability of safe and effective countermeasures against radiological/nuclear threats currently represents a significant unmet medical need. Areas covered: This article reviews the development of RN threat medical countermeasures and highlights those specific countermeasures that have been recently patented and approved following the FDA Animal Rule. Patents for such agents from 2015 have been presented. Expert opinion: Two granulocyte colony-stimulating factor (G-CSF)-based radiation countermeasures (Neupogen® (Amgen, Thousand Oaks, CA) and Neulasta® (Amgen, Thousand Oaks, CA)) have recently been approved by the FDA for treatment of H-ARS and both these agents are radiomitigators, used after radiation exposure. To date, there are no FDA-approved radioprotectors for ARS.

Introduction

Uncontrolled, unwanted radiation exposures as a result of radiologic terrorism, military activity, or nuclear accidents present unique challenges to the medical community and to public health authorities. It is widely acknowledged that terrorist organizations have the capability to obtain or to engineer improvised nuclear devices or other types of radiological dispersal devices [1]. Hundreds of nuclear plants worldwide are at risk of a wide range of natural disasters [2]. Accidents or attacks at these locations could expose first responders and surrounding populations to high, potentially lethal doses of ionizing radiation. Radiation injury and illness may occur after exposures to external radiological/nuclear (RN) sources or to internally deposited RN isotopes, as the latter get incorporated into the cells and tissues of the body after ingestion, inhalation, or transdermal absorption [3]. Cells that are generally most sensitive to radiation are those which rapidly divide such as spermatocytes, hematopoietic stem cells, and intestinal crypt cells. At the subcellular level, ionizing radiation damages normal tissue by causing chromosomal aberrations, altering cell-to-cell communication, perturbing essential membrane functions, changing cytokine production, and inducing inflammation, ultimately slowing tissue repair and killing the cells. The extent of ionizing radiation injury varies depending on the distance from the source of the radiation, rate of exposure, the dose of the exposure, and quality of radiation [4]. The LD50 (50% lethal dose) radiation dose (sparsely ionizing, deeply penetrating ionizing radiation) for humans (uncompromised by infection, etc.) is estimated between 3.5 and 4.5 Gy [5-8]. The latter LD50 estimate is based on the assumption that full supportive care has not been provided; however, with increasing levels and qualities of supportive care, the estimated range of the LD50 values increases, namely, 5.0–6.0 Gy with standard regimens of supportive care and 6.0–8.0 Gy with aggressive supportive care including growth factor and blood transfusions [9].

In case of RN exposure, medical care would be focused initially on the treatment of acute radiation syndrome (ARS), also known as acute radiation toxicity or acute radiation sickness. Once the potential clinical complications of suspected ARS are properly attended to, the medical focus will necessarily shift to treatments associated with managing the more chronic, late-arising injuries and disease processes associated with RN exposures. ARS is defined by the Centers for Disease Control and Prevention as ‘an acute illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating ionizing radiation in a very short period of time (usually a matter of minutes).’ Radiation countermeasures that can lessen or eliminate the impact on health of such types of unwanted RN exposures are urgently needed. The FDA has been and continues to be actively involved in the development of radiation countermeasures. Due to ethical and moral reasons, drugs under development to treat unwanted radiation exposure generally cannot, and should not, be tested for efficacy in healthy human subjects. As a consequence, the FDA developed and implemented an alternative drug approval process involving the use of appropriate animal models to test and evaluate the efficacy of given new medicinals; this new drug approval pathway is commonly referred to as the Animal Rule [10]. This pathway requires efficacy to be demonstrated in one or more animal species that are expected to react with a response predictive for humans, in addition to other criteria [11,12]. Although efforts to produce such medical countermeasures to ARS were initiated more than half a century ago, to date, only granulocyte colony-stimulating factor (G-CSF) (filgrastim, Neupogen) and PEGylated G-CSF (pegfilgrastim, Neulasta) have been approved for hematopoietic acute radiation syndrome (H-ARS) by the FDA (Figure 1) [13-16].

Figure 1.

US FDA-approved countermeasures for RN threats following the Animal Rule and other promising agents. In 2002, the FDA issued the Animal Rule to expedite the development of medical countermeasures against CBRN threats. Since then, 2 countermeasures (*) have been approved by the FDA following the Animal Rule.

In this second part of our two-part article, we have highlighted only those RN threat countermeasures which have been approved following the FDA Animal Rule [11,12] and agents which have been patented in 2014–2015 for RN threats (Table 1). Patent search was executed using the United States Patent and Trademark Office, the European Patent Office (Espacenet), the China Patent and Trademark Office, the Japan Patent Office, and the Canadian Intellectual Property Office websites. We have previously reviewed patents for RN countermeasures during 2011–2014 in recently published articles [13,17].

Table 1.

Patents of countermeasures for ionizing radiation.

Patent number*	Year of publication	Inventor(s)	Molecule/Compound details	Properties
US9017658B2	2015	Burt	Stem cells	Assist in tissue repair
EP2245056 B1	2015	Cerami et al.	Tissue protective peptides	Contain pyroglutamate
US9198914B2	2015	Connell et al.	RAD51 modulator	Enhances DNA repair
US8980574B2	2015	Crapo et al.	Alpha-1 antitrypsin	Prevents and treats radiation-induced necrosis and mucosal injury
US9186406B2	2015	Daly et al.	Purine or pyrimidine nucleosides with antioxidant	Preserve protein function
US8951522B2	2015	Demopulos et al.	MASP-2 inhibitory agent	Blocks/Reduces inflammation
EP2468275B1	2015	Denisenko et al.	Heterocyclic compound	Protects DNA and antimicrobial properties
EP1812555B1	2015	Fong et al.	Myeloid cells	Reconstitutes hematopoiesis
EP2488202B1	2015	Fox et al.	Anti-TNF antibody	Treats GI inflammation
US9216162B2	2015	Goldstein	N-acetylcysteine amide	Counteracts oxidative stress and free radical formation
EP2185581B1	2015	Hesson et al.	Serum amyloid P polypeptide	Treats inflammation and mucositis
EP2578598B1	2015	Hipler et al.	Novel normuramyl glycopeptide compound	Induces certain cytokines and growth factors
JP5777821B2	2015	Inufusa	Composed of Vitamin C, l-glutamine, l-cystine or l-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin	Free-radical scavenger
US8951527B2	2015	Isenberg et al.	Antisense molecules, peptides, and antibodies	Increase cell survival, inhibit TSP-1 and CD47 interaction
CN102821605B	2015	Maniar	α,β-Unsaturated aryl sulfone	Protects normal cells from radiation-induced damage
US8734804B2	2015	Mariusz et al.	Pluripotent stem cells	Rescue hematopoietic and immune systems
CA2673417C	2015	Martin et al.	Benzimidazole	Protects from DNA strand breaks
US8975224B2	2015	Mogelsvang et al.	Serpin molecule	Potent anti-inflammatory agent
EP2310035B1	2015	Okunieff et al.	Fibroblast growth factor	Stimulates hematopoietic stem cell proliferation
EP1539801B1	2015	Pena et al.	Peptides and analogs of heparin-binding growth factors	Induce growth factors/hematopoietic recovery
US9173860B2	2015	Perrine et al.	Compositions comprising S-isomer of α-methyl-hydrocinnamic acid	Stimulate multi-lineage hematopoietic cell production
US9018176B2	2015	Perrine et al.	Benserazide or desloratadine	Treats neutropenia and thrombocytopenia
JP5823486B2	2015	Rodgers	Novel peptide (Nle A(1–7)	Treats combined injury
US9000147B2	2015	Sauve et al.	Nicotinoyl ribosides and nicotinamide riboside derivatives	May inhibit apoptosis
US9045474B2	2015	Schiestl et al.	Two compounds, one is selected from amifostine, growth factors, immune modulators, and antiapoptotic agents	Mitigate radiation-induced tissue damage
US9006183B2	2015	Shakhov et al.	Lipopeptides	Induce NF-κB
US9173922B2	2015	Tingchao et al.	IL-12	Hematopoiesis stimulant
US9120843B2	2015	Turdiev	Tortoise spleen protein extract	Enhances hematopoietic reconstruction
CN103153298B	2015	Vidyasagar et al.	Free amino acids	Treat radiation-induced GI symptoms
US9200035B2	2015	Wipf et al.	Novel oxetane-substituted sulfoxide, sulfide, and sulfone compounds	Radiation mitigator
US9216976B2	2015	Wipf et al.	Nitroxide agents	Free-radical scavenger
CA2668923C	2015	Richter et al.	Tri-substituted glycerol compounds	Cytoprotective
CN103501803B	2015	Xiao-Jing et al.	Smad7	Reduces inflammation
US8734804B2	2014	Marcus	PF4-interacting heparinoids	Promote thrombopoiesis and neutrophil production
US8900635B2	2014	Elder et al.	Nanoparticle isoflavone compositions	Protect DNA
US8784840B2	2014	Gudkov	Recombinant flagellin	Induces NF-κB, modulates apoptosis
JP5389666B2	2014	Shakhov et al.	Lipopeptide	Hematopoietic stem cell mobilizer
US8648042B2	2014	Wang et al.	Pharmaceutical polymer comprising a glycopeptide and an amifostine	Quenches free radicals
US8921315B1	2014	Basile	IL-12 formulation	Preserves bone marrow function
US8916712B2	2014	Basnakian et al.	Zinc chelate	Quenches reactive oxygen species
JP5498940B2	2014	Bemis et al.	Sirtuin-modulating compounds	DNA protectant
CA2645550C	2014	Benner et al.	Novel peptide	Scavenges activated oxygen free radicals and antioxidizing activity
US8765193B2	2014	Djang	Composition of Gynostemma pentaphyllum, Crataegus pinnatifida, and Camellia sinensis	Antioxidant, protects from DNA damage
US8883852B2	2014	Epperly et al.	Glyburide or other sulfonylurea hypoglycemic compounds or potassium channel inhibitors	Protects against cell death resulting from oxidative stress
US8796336B2	2014	Schellenberg et al.	Methoxypolyethylene glycol chelate	Quenches free radicals and removes heavy metals
US8906965B2	2014	Yates et al.	Quinic or shikimic acids	Anti-inflammatory agent
EP2245056 B1	2015	Cerami et al.	Tissue protective peptides	Contain pyroglutamate

*Radiation countermeasure patents from 2014 to 2015. Previously, some of the patents have been filed with another country or region; however, their most recent versions are described above.

All patent references are not provided in this manuscript due to space restrictions. Due to the references limit for this article, citations for each patent presented in this table have not been included in the list of references. Only references that have been cited within the manuscript text have been included in the list of references.

Beginning letters in patent number signifies which patent office approved this property: US: United States Patent and Trademark Office; EP: European Patent Office; CN: China Patent & Trademark Office; JP: Japan Patent Office; CA: Canadian Intellectual Property Office.

GI: Gastrointestinal; IL: interleukin; TNF: tumor necrosis factor.

Countermeasures for radiological and nuclear threats

Whole-body or partial-body exposures to intense, high doses of ionizing radiation often result in life-threatening injuries that primarily involve radiosensitive, self-renewing tissues, but most markedly the hematopoietic and gastrointestinal (GI) systems. Low-dose or chronic ionizing radiation exposures, by contrast, are generally considered the domain of ‘late-arising’ neoplastic pathologies (i.e. cancer). Current RN threats can be categorized into five groups: (a) detonation of a sophisticated nuclear weapon (nuclear bomb), (b) detonation of an improvised nuclear device, (c) use of a radiological dispersal device or dirty bomb, (d) use of a simple radiological device, and (e) an attack on a nuclear power plant [18]. ARS is characterized by the differential response of the body’s vital organ systems to various intensities of radiation exposure. There are at least three distinct subsyndromes: hematopoietic, GI, and neurovascular that are all dependent on the total exposure dose, the exposure dose rate, the quality of radiation, and the time and extent of bodily exposure [19-21]. Cutaneous radiation injury is often linked with ARS but is generally not considered a distinct subsyndrome since one can have cutaneous radiation syndrome without manifesting ARS symptoms. Each subsyndrome follows a similar clinical pattern that is divided into three phases: an initial prodromal phase occurring during the first few hours following exposure, a latent phase that shortens with increasing exposure intensity (total dose and dose rate), and a manifest clinical phase.

ARS

Only two radiomitigators, G-CSF and PEGylated G-CSF, have been approved by the FDA following the agency’s Animal Rule to treat H-ARS. No countermeasures have been FDA approved for the treatment of GI-ARS: radiation-induced neurovascular disorders are largely intractable; therefore, countermeasures for this subsyndrome have not been actively pursued. Radiation countermeasures capable of being administered prior to exposure to protect the population at large from the effects of lethal radiation exposure remain a significant unmet medical need of the US citizenry and have been recognized as a high-priority area by the government [18]. We have limited this article to include agents identified (patents) as potential radiation countermeasures since 2014 (Table 1). There are recent, extensive reviews of this subject that list earlier patents [13,14,17,22].

There are several FDA-licensed pharmaceuticals currently available that safely and effectively mitigate the potentially lethal effects of hematopoietic injury following acute ionizing radiation exposure; these agents include, but certainly are not limited to, G-CSF, PEGylated G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim, leukine), and a filgrastim biosimilar, tbo-filgrastim that have been used in cases of ARS after radiation accidents [15,23]. These growth factors stimulate bone marrow granulopoiesis and have been used successfully in cancer patients to reduce the incidence, duration, and severity of chemotherapy-induced neutropenia and related complications such as febrile neutropenia. As mentioned above, two of these agents, Neupogen and Neulasta, have been approved by the FDA to treat the severe myelosuppression associated with potentially lethal H-ARS. Seven promising drugs that are relatively new currently have FDA Investigational New Drug (IND) status: 5-androstenediol, BIO 300, CBLB502/Entolimod, Ex-RAD, HemaMax, OrbeShield, and myeloid progenitors [13,22,24]. Neupogen and leukine are already in the Strategic National Stockpile (SNS) [25,26]. Further, γ-tocotrienol has advanced to large animal studies [24]. Amifostine, a well-recognized older, but potent radioprotector, has been approved previously by the FDA for limited clinical use, but not specifically for protection against ARS [22].

G-CSF (Neupogen, filgrastim)

G-CSF has been evaluated as a radiation countermeasure in different strains of mice, canines, nonhuman primates (NHPs), and in the minipig [11,15,27-30]. A majority of these studies have used recombinant G-CSF of human origin because G-CSF is not species specific. The results of these studies suggested that G-CSF consistently enhanced survival and the recovery of blood leukocytes (neutrophils) regardless of radiation source (γ-ray, X-ray, mixed field – neutron and gamma). The demonstrated radiation injury mitigating efficacy of G-CSF was dependent on drug dose, the drug treatment schedule in relation to radiation exposure, duration of the treatment, and the dose of radiation [15]. The estimated dose reduction factors for G-CSF were 1.06 [31], 1.1 [32], or 1.2 [33], depending on G-CSF dose, treatment schedule, route of administration, and strains of mice [34]. G-CSF dose modifying factor has also been determined in canine and NHP models [35,36].

In a Good Laboratory Practice compliant study, critical for FDA approval under the criteria of the Animal Rule, G-CSF significantly increased NHP survival after exposure to 7.5 Gy (LD50/60) of linear accelerator-derived photon radiation compared to vehicle controls [36]. G-CSF also decreased the duration of neutropenia but did not affect the absolute neutrophil count nadir. In this study, G-CSF (10 µg/kg/day) was administered beginning 1 day after irradiation and continued daily until the absolute neutrophil count was >1000/µl for 3 consecutive days.

G-CSF was the first agent to be approved by the FDA with the potential to increase survival in patients (both adult and pediatric) acutely exposed to doses of radiation capable of eliciting H-ARS [23,37]. The FDA approved 10 µg/kg/day of G-CSF as the recommended dose for the H-ARS indication on 30 March 2015. G-CSF has also been used in several radiation accident victims with promising outcomes [15]. Studies showed that maximum efficacy is reached with daily dosing of G-CSF early after irradiation; therefore, a subsequent effort with PEGylated G-CSF focused on simplifying the administration schedule of G-CSF while maintaining an equivalent efficacy profile in lethally irradiated NHPs [23,36].

PEGylated G-CSF (Neulasta/pegfilgrastim)

PEGylated G-CSF is G-CSF molecule with the addition of a 20-kD monomethoxypolyethylene glycol (PEG) molecule to the N-terminal methionine residue [38]. PEGylation of G-CSF results in a lower rate of receptor-mediated clearance compared to G-CSF. Consequently, a single dose of PEGylated G-CSF was shown to be as effective as repeated daily doses of G-CSF in reducing the relative risk of febrile neutropenia, decreasing the duration of neutropenia, and shortening absolute neutrophil recovery time after myelosuppressive chemotherapy [15]. Studies in mice and NHPs have shown the comparable efficacy of one or two doses of PEGylated G-CSF, administered weekly, relative to conventional daily administration of G-CSF in reversing neutropenia and enhancing survival, when administered after total-body irradiation [15,16,39-41]. One study demonstrated that two injections of PEGylated G-CSF, separated by 7 days, stimulate granulopoiesis and significantly enhance neutrophil recovery after total-body irradiation in a NHP low-lethality model of H-ARS [39]. In a recent study, two injections of PEGylated G-CSF significantly enhanced survival of NHPs exposed to mid-lethal (LD50/60 for H-ARS) doses of radiation, which resulted in H-ARS. The survival rate of those treated with PEGylated G-CSF was 91.3% (21/23) compared to 47.8% (11/23) in the control group at 60-day postirradiation. PEGylated G-CSF also significantly decreased the median duration of neutropenia and thrombocytopenia, improved the median time to recovery of absolute neutrophil count and platelet count, increased the mean absolute neutrophil count at nadir, and decreased the incidence of gram-negative bacteremia. PEGylated G-CSF was approved by the FDA on 25 November 2015 for use in improving blood profiles of ARS subjects and for increasing survival in patients acutely exposed to myelosuppressive doses of radiation (H-ARS) in both adults and pediatric patients [23,37].

Recent patents for ARS countermeasures

Several radiation countermeasures are in the initial stages of research and development, with a number of them showing effectiveness against radiation injury when administered either before or after irradiation. A large numbers of patents have been recently approved internationally for agents that have radioprotective or radiomitigative potential for ARS [13,14,17]. A list of such agents is presented in Table 1. An ideal drug for FDA approval would work effectively to protect against or treat both H-ARS and GI-ARS. However, since H-ARS and GI-ARS are underpinned by different types of injuries and manifest quite different symptoms, it is appropriate to address them separately during drug development. Some radiation countermeasures are being developed specifically for H-ARS; for example, administration of ET18-0CH3, a phosophocholine, 24 h prior to γ-irradiation appears beneficial to the recovery process [42]. Administration of this agent increases leukocytes and granulocyte levels in blood during the critical period after irradiation and allows animals to survive. An additional cytokine to those already mentioned and that may be administered is interleukin-12 (IL-12, HemaMax). HemaMax has already received FDA IND status. This agent, for which a patent was granted in 2014, has been shown to have radioprotective as well as radiomitigative potential for H-ARS. At low doses (100 ng), IL-12 was able to protect 100% mice against a supralethal radiation dose. This agent has shown consistent efficacy in NHPs [43-45]. IL-12’s efficacy mechanism appears to involve multiple stages of hematopoiesis and includes the induction of IFN-γ [46]. This potential countermeasure has also demonstrated efficacy against lethal combined injury (CI) [47]. Attempts to develop IL-12 as an anticancer immunoadjuvant drug have been complicated by clinical side effects. Novel nitroxide agents have shown radiomitigative potential against H-ARS by scavenging free radicals [48]. Another agent, α-1 antitrypsin (AAT), does not improve survival but allows mice to survive longer than their respective control groups [49]. However, pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), are reduced by AAT while IL-1Rα is upregulated, showing that AAT may be beneficial at the cellular level for recovery after radiation. If this agent is pursued, it may be prudent to combine it with additional countermeasures for optimal efficacy.

Several agents are being developed specifically for GI-ARS [50-53]. Anti-TNF antibody has been tested and proven efficacious to increase survival and to treat GI inflammation [54]. Endogenous production of Smad7, a nuclear regulatory protein, serves to reduce DNA damage and stimulate wound healing [55]. By orally administering Tat-Smad7, damage after high doses of X-ray radiation in the mouse model is minimized (up to 20 Gy). Overexpression of the Smad7 protein does not increase one’s risk of cancer, so this agent may be an attractive candidate for the FDA approval process.

Radiation countermeasures for ARS that might be streamlined for the FDA approval include neutraceuticals, biologicals, and repurposed pharmaceuticals [56,57]. Glyburide is a sulfonylurea that is already approved by the FDA for the treatment of diabetes [58]. It is a blocker of adenosine tripohosphate-sensitive potassium channels and has been shown to regulate apoptosis and mitochondrial permeability. Due to glyburide’s effects on mitochondria and apoptosis, it has been shown to be effective in reducing radiation damage when administered prophylactically, but not following radiation exposure as a radiomitigating agent. Novel biologicals are currently being pursued and include both isolated peptide chains and endogenous proteins. Survival was increased significantly when mice were administered peptide AQGV or the functional peptide of fibroblast growth factor-2 (FGF-P) [59,60]. Peptide AQGV and FGF-P may be viable treatment options after radiation injuries for both H-ARS and GI-ARS, providing an effective treatment at higher radiation doses.

Using a new drug in combination with an already FDA-approved drug may be beneficial to both in terms of improving drug efficacy as well as from a strategic standpoint to move the test drug through the FDA regulatory process. For example, poly-glutamic acid amifostine (GP-A) may be a useful pharmaceutical polymer due to its relationship with amifostine, an FDA-approved radiation countermeasure for limited use [61]. GP-A prolongs the retention time of amifostine within organs and protects DNA from free-radical damage resulting from ultraviolet rays. Neutraceuticals are natural products commonly used globally for the treatment of various diseases. In non-Western cultures, traditional medicine is practiced more commonly. One recently published patent combines jiaogulan (Gynostemma pentaphyllum), hawthorn (Crataegus pinnatifida), and green tea (Camellia sinensis) extracts for a radioprotective efficacy at low doses of X-ray irradiation [62]. There are large numbers of recently isolated agents promising for future developments (Table 1). Some agents have shown more promise than others depending on the model being used (single vs. multiple strains of mice).

Countermeasures for radioisotope-specific toxicities

It needs to be pointed out that there are several, already established, highly efficacious drugs for the prophylaxis and/or treatment of individuals contaminated with selected types of radionuclides; these drugs include potassium iodide (KI; ThyroShield) for the protection of the thyroid gland from radioactive iodine, prussian blue (PB; Radiogardase) for the treatment and reduction of radioactive cesium body burdens, Zn/Ca DTPA (Zn/Ca diethylene triamine pentaacetic acid) for the treatment of plutonium contamination, and Granisetron/Kytril for blocking/minimizing emetic effects of ARS [22]. PB, Zn/Ca DTPA, and Granisetron, all are available in the SNS [22].

CI treatments

During a nuclear accident or terrorist attack, the likelihood of a blast following a radioactive explosion is high, which will result in thermal burns, wounding, or hemorrhage in addition to radiation exposure; the victim of such combined exposures would then be classified as having a CI [63-65]. The adverse biological effects induced by CI act synergistically against the host’s survival; wounds or burns in radiation survivors are known to exacerbate ARS, including enteropathy associated with hematopoietic syndrome [7,8]. Radiation exposure is known to compromise the victim’s immune system; opportunistic endogenous bacterial colony can then infect non-sterile wounds or burns, ultimately resulting in sepsis [66]. Polymicrobial septic infections consisting of multiple microorganisms, each having different characteristics, means of defense, and antimicrobial susceptibilities, will accompany injuries from the direct radiation exposure or the CI, especially following LDs of γ-radiation [67,68]. Polymicrobial infections are often especially challenging and limit the effectiveness of conventional therapy.

It has been shown that supportive care alone increases survival chances after ionizing radiation exposure [29]; standard supportive care includes fluid administration, antibiotics, analgesics for pain, antipyretics for fever, and blood product transfusions. CI patients may be administered topical ointments to clean burns and wounds and antibacterial/antimicrobial agents to prevent sepsis. Survival rates increase in CI individuals with supportive care. No drug to date has been approved to specifically treat CI. There are, however, several drugs that appear to increase recovery and promote survival when administered concomitantly with other ionizing radiation injury-specific treatments [7,63,69,70].

Only a few agents have recently been patented to specifically treat after CI. NorLeu3-A (1–7), a heterocyclic compound, increased survival and proliferating epidermal tissue around the burn site in thermal injury-CI model of guinea pigs when administered within 3 days of 2 Gy irradiation and applied daily (doses as low as 10 µg/wound) [71]. This compound also decreased wound healing delay after thermal wound and 6 Gy exposure when administered at 1 mg/ml/day per wound. A group of novel drugs related to 3,4-methylenedioxy-β-methyl-β-nitrostyrene were able to increase the survival rate at 25 days postirradiation exposure when administered 1–2 days before 2–20 Gy irradiation. The drugs in this particular group were not tested for CI directly, instead were tested as radiation and infection treatments separately. They displayed antimicrobial properties toward several bacteria when topically administered to wounds in human volunteers and mice [72].

Conclusion

Though G-CSF has been approved by the FDA for H-ARS and has already been procured, along with GM-CSF, for the SNS for use in a RN emergency [23,73], the adverse effects of G-CSF need to be taken into consideration [74-76]. The International Atomic Energy Agency recommends that platelet counts be monitored during G-CSF administration which will be difficult in a mass causality scenario [77]. It is important to note that in a recent study, G-CSF failed to demonstrate radiomitigative efficacy in the NHP model in the absence of supportive care [45]. This observation might be critical in terms of developing medical plans for managing mass casualties arising from unwanted RN exposures and the possible limits of delivering conventional supportive care to the RN injured. It would seem prudent to both acknowledge the effectiveness of recombinant therapies, such as G-CFS and GM-CSF, and to fully recognize the limitations of such therapies, while continuing search for new, still more effective medical countermeasures to RN exposures. Although, the cause for the disparate research findings mentioned above remains unclear, there is still a pressing need to develop radioprotectors which can be administered prior to irradiation. Such agents should demonstrate efficacy in the absence of supportive care as such infrastructure may not be available to all victims under a large-scale mass causality scenario.

Expert opinion

The Animal Rule was developed to provide a pathway for the approval of a drug or licensing of biologic products for use in chemical, biological, radiological, or nuclear (CBRN) exposure contingencies without having human efficacy data; the alternative, which is clearly unacceptable, was to leave these products in regulatory ‘limbo’ as INDs and their utility would be significantly weakened by virtue of the fact that a medicinal bearing an IND label would first require informed consent (from the patient) prior to use. The US government has taken quite laudable steps to protect its citizens in the event of a public health emergency by developing a system to procure essential medical countermeasures for CBRN threats. In this regard, promising medical countermeasures do not necessarily require full FDA approval or licensure in order to be produced, stockpiled, and made readily available in the event of a mass casualty scenario. Authorization of these IND-bearing medicinals (commonly referred to as medical countermeasures) under an emergency use provision of the ‘Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013’ is quite possible, but not without being bureaucratically cumbersome and time-consuming during critical emergency situations [73].

Emergency Use Authorization (EUA) is an important option for medical and public health. It complements the need for timely and useful treatment when the applicable drug has not been approved at all or approved for another specific indication by the FDA [78]. The EUA authority under Section 564 permits the FDA to facilitate availability and use of medical countermeasures required to prepare for and respond to CBRN disasters. PAHPRA improved the current EUA authority to better serve rapid response to public health emergencies. Specifically, by eliminating the need for the original Project BioShield that Department of Health and Human Services secretarial determination in support of an EUA takes the form of an official public health emergency declaration, PAHPRA is designed to facilitate preparation for both actual and potential public health emergencies [73].

There are in fact multiple, highly effective, and essential medical countermeasures that carry only IND status [13,22]. The EUA requires a reasonable database in both the clinic and animal models. G-CSF and GM-CSF were recommended for EUA status due to the overwhelming, consistent safety and efficacious clinical and preclinical database in multiple species. G-CSF and GM-CSF were procured for the SNS much before FDA’s approval of G-CSF for treatments of H-ARS under the PAHPRA [15,73,79].

The Animal Rule requires a comprehensive understanding of the mechanisms of injury, drug efficacy, and efficacy biomarkers. In this context, it is important to identify biomarkers for radiation injury and drug efficacy that can extrapolate animal efficacy results to convert drug doses to those that can be efficacious when used in humans [11,24]. It is important to note that the pharmacokinetic profile across species should be considered to insure appropriate dosing of the drug in animal models. Biomarkers are an important aspect of radiation countermeasure development and can be used as a trigger for intervention as well as in selecting a drug dose and treatment regimen in humans. Biomarkers may also be shown to correlate with the mechanism by which the agent reduces the injury inflicted or with the desired clinical outcome (i.e. reduction in mortality or major morbidity). The human dose of the drug should closely correlate with efficacious doses from the well-controlled animal studies [12,80].

GI-ARS is a major, potentially lethal pathological response that may occur soon after a radiation/nuclear incident [3,81]. Currently, there are no prophylactic countermeasures that are FDA approved for the GI syndrome lethality. Clearly, this deficit represents a major unmet medical need in terms of protecting first responders, military personnel, or remediation workers entering a contaminated area. Both, Neupogen and Neulasta, are effective against H-ARS only and have limited efficacy. Again, there is a significant need to develop safe and effective countermeasures against supralethal doses of radiation causing GI-ARS. The pathophysiology of this syndrome requires depletion of stem cells (stem cell clonogens [SCCs]) within the crypts of the Lieberkuhn, a subset of cells necessary for post-injury regeneration of GI epithelium. Recent studies indicate that depletion of SCCs is not a direct result of DNA damage, but instead coupled to ceramide-induced endothelial cell death (apoptosis) within the mucosal microvascular network. The ceramide generated on the surface of endothelium coalesces to form ceramide-rich platforms and these platforms serve to transmit apoptotic signals [82,83]. Administration of an anti-ceramide monoclonal antibody prevents platform formation on the surface of irradiated endothelial cells of the murine GI tract and, in turn, limits the extent of radiation-induced endothelial apoptosis within the lamina propria of the small intestinal and facilitates recovery of crypt SSCs, thus sparing experimental animals (mice) from early death associated with GI-ARS after supralethal radiation exposures. This antibody represents a new class of therapeutics, with a promising future as an effective countermeasure against GI-ARS mortality [84].

There are several promising radiation countermeasures (other than those listed above) under advanced stages of development for RN threats which have been discussed in recent reviews [13-15,17,22,57,65]. In addition to two approved H-ARS countermeasures, CBLB502 (Entolimod) is at an advanced stage of development. Its pre-EUA dossier is currently under active review with the FDA [85,86]. HemaMax (IL-12) is progressing well with evaluation in large animals [45,46]. γ-Tocotrienol is another promising radiation countermeasure under advanced development [87-89].